CTLA4 and cancer: More speculatively, recent advances in solid tumour immunotherapy using monoclonal antibody “check-point” inhibitors against CTLA4 and PD1/PD1L to reactivate anti-cancer cytotoxic immune defences show that active inflammation and active NK attack are integral to inducing tumour regression [46].